Seeking Alpha

  PAREXEL International Corporation - NASDAQ

10/24/2014, 8:56 PM ET
  • Alex B. Gray | Send Message 2 Nov 2010

    Parexel $PRXL reported FY2011 Q1 revenue increased 13.9% to $295.8M and diluted earnings per share increased 42.9% to $0.30.
      PRXL vs. ETF Alternatives
      Company Description
      Parexel International Corp is a biopharmaceutical company, providing clinical research, medical communications services, consulting, and informatics and advanced technology products and services to the pharmaceutical and biotechnology.